Diabetes mellitus (DM) is becoming a global public health issue.  Mushrooms have been used as a neutraceutical as well as for medicinal   puposes. In the present study Coprinus atrimenteria was evaluated against the in-vitro anti-oxidant and anti-diabetic assay using DPPH, ABTS, H₂O₂ and α-amylase, β-glucosidase inhibitory effects respectively. Maximum efficacy was observed in ABTS activity (60%) followed by H₂O₂ and DPPH as compared with control (Ascorbic Acid). Similarly the methanol extract showed a significant inhibitory effects of α-amylase (65.89%) and β-glucosidase (59.89%) accordingly as compare with standard anti-diabetic drug Glucophage (86.34%). The mushrooms C. atrameneria showed a significant increase in body weight in comparison with diabetic control and a remarkable decrease in random blood glucose level (RBG). Similarly the Lipid Profiles (TC, LDL, HDL, TG) of albino rats were analyzed and found significant as compare with normal control. These results suggest that C. atramenteria   mushroom species could be hopefully used as an antioxidant and as alternative medicine for the treatment of diabetes mellitus.

Key Words; Coprinnus atrementeria mushroom, anti-oxidant, In-vitro, In-vivo-anti-diabetic potentials.